…
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Income before tax | -3.19M | -1.77M | -2.29M |
| Net income | -3.19M | -1.77M | -2.29M |
| Selling general administrative | 5.59M | 1.55M | 2.30M |
| Reconciled depreciation | 0.05M | 0.05M | 0.04M |
| Ebit | -3.19M | -1.77M | -2.29M |
| Ebitda | -3.14M | -1.72M | -2.25M |
| Depreciation and amortization | 0.05M | 0.05M | 0.04M |
| Operating income | -5.86M | -1.80M | -2.31M |
| Other operating expenses | 5.86M | 1.80M | 2.31M |
| Interest income | 0.03M | 0.03M | 0.02M |
| Net interest income | -0.47M | 0.03M | 0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 5.86M | 1.80M | 2.31M |
| Total other income expense net | 2.66M | 0.03M | 0.02M |
| Net income from continuing ops | -3.19M | -1.77M | -2.29M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Total assets | 12.16M | 2.05M | 2.01M |
| Intangible assets | 0.92M | 0.82M | 0.77M |
| Other current assets | 0.12M | 0.23M | 0.02M |
| Total liab | 7.48M | 2.23M | 1.93M |
| Total stockholder equity | 4.69M | -0.18M | 0.09M |
| Other current liab | 3.03M | 0.67M | 0.46M |
| Common stock | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M |
| Retained earnings | -22.39M | -19.20M | -17.43M |
| Cash | 5.08M | 0.87M | 1.18M |
| Total current liabilities | 6.00M | 0.71M | 0.49M |
| Net debt | -5.00M | -0.75M | -1.16M |
| Short term debt | 0.05M | 0.04M | 0.03M |
| Short long term debt total | 0.08M | 0.12M | 0.03M |
| Other stockholder equity | 27.07M | 19.02M | 17.51M |
| Total current assets | 5.20M | 1.10M | 1.20M |
| Accounts payable | 2.93M | - | - |
| Non currrent assets other | 6.04M | 0.01M | 0.01M |
| Non current assets total | 6.97M | 0.95M | 0.81M |
| Capital lease obligations | 0.08M | 0.12M | 0.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Investments | - | -0.10M | -0.04M |
| Total cashflows from investing activities | -0.15M | -0.10M | -0.04M |
| Total cash from financing activities | 6.92M | 1.15M | 0.50M |
| Net income | -3.19M | -1.77M | -2.29M |
| Change in cash | 4.20M | -0.31M | -0.92M |
| Begin period cash flow | 0.87M | 1.18M | 2.10M |
| End period cash flow | 5.08M | 0.87M | 1.18M |
| Total cash from operating activities | -2.56M | -1.36M | -1.38M |
| Issuance of capital stock | 6.92M | 1.15M | 0.50M |
| Depreciation | 0.05M | 0.05M | 0.04M |
| Other cashflows from investing activities | -0.15M | - | - |
| Capital expenditures | 0.15M | 0.10M | 0.04M |
| Change in working capital | 2.37M | -0.00M | 0.23M |
| Stock based compensation | 0.42M | 0.35M | 0.64M |
| Other non cash items | -2.21M | 0.01M | 0.00M |
| Free cash flow | -2.72M | -1.46M | -1.42M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| TTRX Turn Therapeutics Inc. Common Stock |
-0.25 2.81% |
8.64 | - | - | - | 596.40 |
| NVO Novo Nordisk A/S |
-0.54 1.36% |
38.90 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
- -% |
520.66 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
2.34 0.25% |
923.34 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 |
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
250 N Westlake Blvd, Westlake Village, CA, United States, 91362
818 546 4011
2
| Name | Title | Year Born |
|---|---|---|
| Mr. Bradley E. Burnam | Founder, CEO & Director | 1980 |
| Mr. Zuraiz Chaudhary | Interim CFO, VP of Finance & Chief Accounting Officer | 1996 |
| Dr. Neilesh Shailesh Ghodadra M.D. | Chief Medical Officer & Director | 1981 |
| Mohammed Zubair | Controller | NA |
| Dr. Stephen M. Hahn FASTRO, M.D. | Executive Clinical & Regulatory Lead | 1960 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.